US 2017/0283406 A1 · HETEROCYCLIC COMPOUND

Abstract

The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Claims16

Dependent claims

A compound represented by the formula (I):

wherein
Ring A is an optionally further substituted ring,
Ring D is an optionally further substituted ring,
n is 1 or 2,
X is —O—, —CR1R2—, —CR1R2—O—, —O—CR1R2— or —NR3—,
R1, R2 and R3 are each independently a hydrogen atom or a substituent, and
Ra and Rb are each independently a hydrogen atom or a C1-6 alkyl group optionally substituted by halogen atom(s),
or a salt thereof.

5 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/474,192Filed 30 Mar 2017

Priority

JP 2016-07118131 Mar 2016

Published

5 Oct 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07D 413/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms:…
A61P 21/02
Drugs for disorders of the muscular or neuromuscular system: muscle relaxants, e.g. for tetanus or cramps
A61P 25/00
Drugs for disorders of the nervous system
A61P 25/04
Drugs for disorders of the nervous system: centrally acting analgesics, e.g. opioids

Heterocyclic compound

Life of this patent

Heterocyclic compound

Life of this patent

Abstract

Claims16